Drug Discovery World

DECEMBER 7, 2023

New guidance for the motor neuron disease (MND) drug discovery community has been published to ensure that future drug discovery and development efforts have the best chance of successfully translating from the lab to the clinic. The Guiding Principles underpin a new £5 ($6.2)

Bioinformatics 130

Bioinformatics Clinical Trials Drugs Trials 130

Drug Discovery World

APRIL 14, 2023

The headlines our attention this week all represent significant breakthroughs in the treatment of various diseases and could make a huge difference to the lives of these patients. There is also new hope for sepsis treatment and for preventing cardiovascular disease in people with HIV thanks to recent research.

Vaccine 130

Vaccine Clinical Trials Drugs Pharmaceutical Companies 130

Drug Discovery World

JULY 16, 2024

The World Health Organization has announced a goal of reducing the global burden of snakebite in half by 2030. Cobras kill thousands of people a year worldwide and many more are seriously maimed by necrosis caused by the venom, which can lead to amputation.

Science 130

Science Treatment Drugs Disease 130

Drug Discovery World

AUGUST 18, 2023

The money is intended to pay for new laboratories, disease surveillance systems, and a bigger global workforce. billion to bring new antibiotics to market by 2030 through the AMR Action Fund. The announcement follows the £39 ($48) million investment through the Global AMR Innovation Fund (GAMRIF) in May.

Laboratories 236

Laboratories Government International Hospitals 236

Drug Discovery World

FEBRUARY 28, 2023

The funding will drive proprietary research into novel compounds that extend healthy lifespan of cells and tissues, with therapeutic potential across a broad range of age-related diseases. billion by 2030. Globally, the anti-ageing therapeutics market is expected to reach $2.01 Anti-ageing science therefore has huge value.

Small Molecule 130

Small Molecule Disease Science Treatment 130

The Pharma Data

MAY 26, 2023

More ways, to save more lives, for less money: World Health Assembly adopts more Best Buys to tackle noncommunicable diseases The World Health Organization has expanded the list of ‘NCD best buys’. The report is part of the NCDs Global Action Plan 2023-2030 and is an update from 2017 and is core to the Implementation Roadmap on NCDs.

Disease 52

Disease Government Treatment Production 52

Drug Discovery World

FEBRUARY 1, 2024

These deposits can cause progressive damage to the brain and other areas of the body. Disease symptomatology is characterised by chronic diarrhea during infancy and cataracts in late childhood. At present there is no cure for CTX, only treatment to slow disease progression. Vivet Therapeutics has received €4.9

Therapies 130

Therapies Treatment Disease Virus 130

Drug Discovery World

DECEMBER 12, 2023

Exonate has now regained full rights to its complete portfolio of ophthalmology assets from Janssen Pharmaceuticals EXN407 is reportedly well placed to be the first topical treatment for retinal vascular diseases, including diabetic retinopathy and diabetic macular oedema. EXN407 is a small molecule inhibitor of splice factor kinase SRPK1.

Small Molecule 130

Small Molecule Trials Pharmacokinetics Treatment 130

Drug Discovery World

MAY 6, 2024

The company is now investigating a promising gene therapy for Huntingdon’s disease in a Phase I/II trial, with patients already showing signs of preserved neurological function. billion) Healthcare Innovation 2030 project, with ambitious plans to turn France into the European leader in health innovation by 2030. billion ($7.9

Drugs 148

Drugs Science Molecular Biology Clinical Trials 148

The Pharma Data

MAY 31, 2022

The initiative is supported by a multidisciplinary Steering Committee of patient advocacy leaders, healthcare professionals, biosimilar experts and industry leaders from around the world, with a mission to increase global adoption of biosimilar medicines by at least 30% in 30+ countries by 2030.

Biosimilars 52

Biosimilars Treatment Government Hospitals 52

Drug Discovery World

APRIL 16, 2024

ALS is a fatal neurodegenerative disease affecting 50,000 individuals in Europe at any time, resulting in 10,000 deaths each year. Currently, there is no cure for ALS and the only approved drug in the EU for the disease is Riluzole, prolonging survival for a median of just two months.

Clinical Trials 130

Clinical Trials Trials Pharmacokinetics Drugs 130

The Pharma Data

OCTOBER 25, 2021

It further evolves Boehringer Ingelheim’s commitments and significantly increases the company’s donation to appreciatively impacting health, societal and environmental issues, in alignment with the United Nations 2030 Sustainable Development Goals.

Vaccine 52

Vaccine Hospitals Disease Production 52

Antidote

AUGUST 2, 2022

Mitral valve regurgitation is a common kind of heart disease in the United States. Not only does it impact many people today, but its prevalence is expected to double by 2030.

Disease 98

Disease 98

The Pharma Data

APRIL 12, 2022

WHO welcomes the establishment of a new Heads of State and Government Group to accelerate progress towards the SDG target for noncommunicable diseases ? a one-third reduction in “premature” deaths from diseases like diabetes, cancer, heart and lung disease and the promotion of mental health and well-being.

International 52

International Disease Government Production 52

Drug Discovery World

OCTOBER 18, 2023

Adeno-associated virus (AAV) vector-based gene therapies hold exceptional promise across a range of disease areas. Such therapies have become an appealing drug modality for multiple conditions, including monogenic disorders, cancers, and infectious diseases. Accessed 26 Jul 23. Available at [link] 2: U.S. Accessed 26 Jul 23.

Therapies 163

Therapies Clinical Trials FDA Approval Virus 163

The Pharma Data

NOVEMBER 12, 2020

Committee A, which focuses on programme and budget matters, decided to recommend the adoption of the first-ever resolution on meningitis, which would approve a global roadmap to defeat meningitis by 2030 – a disease that kills 300,000 people annually and leaves one in five of those affected with devastating long-term consequences.

Disease 52

Disease Treatment 52

Drug Discovery World

JANUARY 19, 2023

Worryingly, according to the United Nations, national climate plans for parties to the Paris Agreement would bring us back to 2010 emission levels, leading to a rise of around 11% in greenhouse gases by 2030.

Pharmaceuticals 130

Pharmaceuticals Pharmaceutical Companies Clinical Trials Government 130

The Pharma Data

OCTOBER 9, 2021

Alzheimer’s is the most common form of madness, which presently affects farther than 55 million people worldwide, and is projected to reach 78 million by 2030. trillion per space by 2030. Much 10 million people widely are diagnosed with Notice each space.

Disease 52

Disease FDA Therapies Testimonials 52

The Pharma Data

OCTOBER 14, 2021

Food and Drug Administration (FDA) for the treatment of people living with Alzheimer’s disease (AD). “This Breakthrough Therapy Designation reinforces our confidence in gantenerumab, which would be the first subcutaneous medicine for the treatment of Alzheimer’s disease with the potential for at-home administration.

Disease 52

Disease Therapies FDA Trials 52

The Pharma Data

JANUARY 26, 2021

27, 2021 /PRNewswire/ — BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office (EPO) has issued a decision to grant European patent EP 2 448 968 B1 for novel antibodies that could be developed into a treatment for Alzheimer’s disease. STOCKHOLM , Jan. About BioArctic AB.

Disease 40

Disease Pharmaceutical Companies Licensing Licensing 40

Drug Target Review

SEPTEMBER 21, 2023

Some report that they believe that if they don’t take the medication, they may develop onchocerciasis-related severe skin diseases and may go blind (river blindness) and would prefer a treatment that does not repeat every year. Need for adulticidal drugs More than 99 percent of countries worldwide has been affected by this disease.

Drugs 105

Drugs Treatment Disease Research 105

The Pharma Data

JUNE 28, 2021

Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company’s (NYSE: LLY) investigational antibody therapy for Alzheimer’s disease (AD). Dementia due to Alzheimer’s disease is the most common form of dementia, accounting for 60 to 80 percent of all cases 1.

Therapies 40

Therapies Disease Treatment FDA Approval 40

The Pharma Data

MARCH 9, 2021

New data from 10 studies will be presented by Eli Lilly and Company (NYSE: LLY) at the upcoming virtual International Conference on Alzheimer’s & Parkinson Diseases 2021 (AD/PD 2021), March 9-14, 2021. vice president of Alzheimer’s disease development unit, Eli Lilly and Company.

Disease 40

Disease International Research Therapies 40

The Pharma Data

JULY 27, 2021

AbbVie (NYSE: ABBV) and Calico Life Sciences today announced an extension of their leading-edge collaboration to discover, develop and bring to market new therapies for patients with age-related diseases, including neurodegeneration and cancer. This is the second extension of the collaboration originally established in 2014. Levinson, Ph.D.,

Disease 52

Disease Science Production Therapies 52

The Pharma Data

NOVEMBER 2, 2020

million people were treated for lymphatic filariasis (LF) in 38 countries that implemented mass drug administration (MDA) of populations at risk of the disease, as recommended by the World Health Organization (WHO). million people no longer require MDA for this debilitating parasitic disease. Setting sights on 2030.

Packaging 52

Packaging Disease Treatment Drugs 52

New Drug Approvals

JANUARY 31, 2024

In addition to hyperlipidemia and type 2 diabetes, a marked increase in the prevalence of non-alcoholic fatty liver disease (NAFLD) has occurred. Preparation of benzoic acid derivatives for treatment of metabolic and liver diseases. Current drugs that treat hyperlipidemia (e.g., twitter +919321316780 call whatsaapp EMAIL.

Treatment 52

Treatment Disease Pharmaceuticals Drugs 52

Drug Discovery World

APRIL 25, 2023

Alba Health which is on a mission to reduce chronic disease risks from childhood, leveraging data science and the latest microbiome science. Amplify Therapeutics boasts disease-modifying therapies for Gaucher disease and genetic subgroups of Parkinson’s disease. billion by 2030.

Science 130

Science Small Molecule Disease Government 130

Drug Discovery World

JULY 31, 2023

DDW’s Reece Armstrong speaks to Hendrik Streefkerk , Chief Medical Officer and Drug Safety Officer of CellProthera about the company’s cell therapy for acute myocardial infarction (AMI) and why regenerative medicine could be key to treating cardiac diseases. million people every year. T his is the market CellProthera wants to enter.

Clinical Trials 130

Clinical Trials Hospitals Therapies Trials 130

Drug Discovery World

MARCH 2, 2023

Going through the timeline of advances in this area, he initially focused on leukaemia as a success story in stem cell cancer treatment, and how researchers realised T cells from stem cell donors were eliminating residual cancer but also brought the risk of graft versus host disease (GvHD). The post Precision cancer therapies: Where are we?

Therapies 130

Therapies Treatment Trials Disease 130

Drug Target Review

SEPTEMBER 22, 2023

The substantial value of organoids is becoming increasingly recognised by supportive government initiatives developing novel drugs, with a growth rate of 22 percent between 2023 and 2030 and a market size predicted to reach over US $6.5 billion by 2030. CRISPR engineering in organoids for gene repair and disease modelling.

Clinical Research 116

Clinical Research Research Drug Development Molecular Biology 116

The Pharma Data

MARCH 11, 2021

Access to broader reliable diagnostic solutions helps healthcare communities working to expedite and increase disease elimination programs. Roche’s Global Access Program provides innovative diagnostic solutions improving disease and patient ma. Without accurate diagnosis, appropriate disease management may be delayed.

Disease 52

Disease Laboratories Treatment Virus 52

LifeSciVC

JANUARY 16, 2024

Naturally many of these acquisitions are driven by enthusiasm for clinical-stage assets that may contribute meaningfully to revenues in 2030+, and we are seeing Pharma build deeply in several key areas (obesity, immunology, oncology, neuro) as they add on to existing franchises or build new ones. Join the club. Additional trials (e.g.,

Small Molecule 140

Small Molecule Trials Therapies Disease 140

Drug Discovery World

OCTOBER 6, 2022

until 2030. This growth is due to factors including a rise in speciality medicines, an increase in lifestyle-driven diseases and a growing population 1. The European drug discovery sector is buoyant. Valued at $14.8 billion in 2020, the sector is expected to grow by 8.3%

Targeted Protein Degradation 130

Targeted Protein Degradation Drugs Pharma Companies Marketing 130

The Pharma Data

APRIL 7, 2021

Thirty of Sanofi’s medicines will be provided across a wide range of therapeutic areas, including cardiovascular disease, diabetes, tuberculosis, malaria and cancer. In December 2020, Sanofi announced it had renewed its five-year partnership with WHO to fight neglected tropical diseases that affect approximately one billion people.

Packaging 52

Packaging Vaccine Disease Treatment 52

The Pharma Data

OCTOBER 29, 2020

Scaling up efforts on the prevention and control of non-communicable diseases (NCDs) can avert over 4.3 before the age of 70) from one of the four main NCDs – cardiovascular diseases, cancer, diabetes, and chronic respiratory diseases. million deaths and yield RUB 8.1

Disease 40

Disease Packaging Government Production 40

The Pharma Data

MARCH 13, 2021

Further, prespecified exploratory analyses showed donanemab slowed the accumulation of tau across key brain regions in patients affected by Alzheimer’s disease. “This is the first late-stage study in Alzheimer’s disease to meet its primary endpoint at the primary analysis. Apostolova, M.D.,

Disease 40

Disease Trials Treatment Medical Schools 40

The Premier Consulting Blog

MAY 4, 2023

billion in 2022 and is expected to grow approximately eight percent from 2023 to 2030 [1]. Ophthalmic drugs market size, share & trends analysis report by drug class, by disease (dry eye, glaucoma), by dosage form, by route of administration, by product type (prescription, OTC), by region, and segment forecasts, 2022-2030.

FDA 52

FDA Packaging Compliance Regulations 52